

For Immediate Release
www.bio.org

Press Contact: Erin Reese
202-962-9235
Investor Contact: John Craighead
202-962-6632

BIO Investor Advisory: BIO Announces Must-See Therapeutic Workshop Topics for Seventh Annual BIO Investor Forum

Hematology, Fibromyalgia, Osteoporosis, Huntington's Disease, Cystic Fibrosis and More to be Showcased

WASHINGTON, DC – (September 25, 2008) – The Biotechnology Industry Organization (BIO) today announced the final selection of therapeutic workshops to be presented at the Seventh Annual BIO Investor Forum, taking place October 29-31, 2008 at the Palace Hotel in San Francisco, Calif. Experts chosen to speak on these panels represent leading clinical institutions, medical foundations, and public and private biotechnology companies.

“In order to augment the high caliber of our program, each therapeutic session is focused on near-term catalysts such as upcoming regulatory approvals, clinical data reporting, FDA Advisory Committee meetings, or prospective partnering opportunities,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “This rigorous vetting process has resulted in a can’t-miss roster of sessions.”

The BIO Investor Forum’s therapeutic workshops will offer a selection of topics addressing the latest developments in therapies for a wide range of diseases. This year’s therapeutic workshop topics include:

Hematology: Pre-ASH Primer: Hematology Heavy Hitters Discuss What’s on the Horizon *Thursday, October 30, 9am-10:45am*

Moderator: Reni Benjamin, Senior Biotech Analyst, Managing Director, Rodman & Renshaw
Industry: Celator Pharmaceuticals
Clinician: Frank Giles, MD, Director of Institute for Drug Development and Chairman of the Division of Hematology and Medical Oncology, University of Texas Health Sciences Center, San Antonio

Fibromyalgia: First Things First - New Approaches to Treating Fibromyalgia are Coming into Focus but Where do Clinicians Start?

Thursday, October 30, 9:00am-10:45am

Moderator: Corey Davis, Managing Director, Senior Specialty Pharmaceuticals Analyst, Natixis Bleichroeder

Advocacy: National Fibromyalgia Association

Clinician: Philip Mease, MD, Director of Seattle Rheumatology Associates, Director of the Swedish Hill Hospital Rheumatology Clinical Research Division, Clinical Professor, University of Washington, Seattle
I. Jon Russell, MD, PhD, Director of the University Clinical Research Center, Associate Professor of Medicine, University of Texas Health Science Center, San Antonio
Andrew Holman, MD, Associate Clinical Professor of Medicine, University of Washington, Seattle

Epilepsy: Targeting Seizures Disorders - A Pipeline at the Threshold of a Broader CNS Opportunity

Thursday, October 30, 9:00-10:45am

Moderator: Sam Wertheimer, PhD, Private Equity Partner, Orbimed
Industry: Marinus Pharmaceuticals
Clinician: Roger Porter, MD, Adjunct Professor of Pharmacology, Uniformed Services University of the Health Sciences, Philadelphia
David Treiman, MD, Newsome Chair in Epileptology, Director of the Epilepsy Center, Vice-chair of Neurology at the Barrow Neurological Institute in Phoenix, Professor of Neuroscience and Bioengineering at Arizona State University, Tempe

Congestive Heart Failure: New Therapeutics to Improve CHF Outcomes

Thursday, October 30,, 9:00-10:45am

Moderator: Michael G. King, Senior Biotech Analyst, Director of Research, Rodman & Renshaw
Industry: Cytokinetics
Clinician: John Teerlink, MD, Associate Professor of Medicine, University of California, San Francisco, Director of the Heart Failure Clinic, Director of Clinical Echocardiography at the San Francisco Veterans Affairs Medical Center

Osteoporosis: Opportunity in Osteoporosis and Bone Metabolism Disorders is Spurring Pipeline Growth

Thursday, October 30, 5:00-6:10pm

Moderator: Liana Moussatos, Senior Biotechnology/Biopharmaceutical Analyst, Pacific Growth Equities
Industry: Osteologix
Zelos Therapeutics
Clinician: Michael McClung, MD, Founding Director, Oregon Osteoporosis Center, Portland
John Bilezikian, MD, Chief of Metabolic Disease Unit, Chief of the Division of Endocrinology and Professor at the College of Physicians and Surgeons, Columbia University, New York

Cancer: Bullseye: Novel Targets in Oncology

Thursday, October 30, 5:00-6:10pm

Moderator: Jason Kantor, Managing Director, RBC Capital
Industry: Curis
Proteolix, Inc.
Clinician: Sunil Sharma, MD, Chief of the Section of GI Oncology and Clinical
Phase 1 Unit at Nevada Cancer Institute, Las Vegas

Lung Cancer: Changing Paradigms in Lung Cancer Care and Advances in the Pipeline

Friday, October 31, 9:45-11:00am

Moderator: Gregory Frykman, MD, Senior Vice President and Pharmaceutical
Analyst,, Stanford Group
Industry: GlobeImmune
Clinician: Thomas J. Lynch, MD, Chief of Hematology and Oncology, Director of
the Center for Thoracic Cancers at Massachusetts General Hospital,
Professor of Medicine at Harvard Medical School

**Huntington's Disease: A Focus on Neurodegeneration - Huntington's and Parkinson's
Diseases**

Friday, October 31, 9:45-11am

Moderator: William Ho, Senior Biotech Analyst, Bank of America Securities
Industry: Medivation
Ceregene
Clinician: Michael Geschwind, MD, PhD, Assistant Professor of Neurology,
University of California, San Francisco

Cystic Fibrosis: Come up for Air! What's in the Pipeline for Cystic Fibrosis?

Friday, October 31, 9:45-11:00am

Moderator: Liana Moussatos, Senior Biotechnology/Biopharmaceutical Analyst,
Pacific Growth Equities
Industry: Inspire Therapeutics
PTC Therapeutics
Clinician: Richard Moss, MD, Professor of Pediatrics, Director of Cystic Fibrosis
Center, Chief of the Division of Allergy- Immunology, Stanford
University
L. Terry Spencer, MD, Director of Cystic Fibrosis Center, Director of
Clinical Research, Division of Respiratory Diseases, Children's Hospital
Boston

To learn more about the BIO Investor Forum, including registration and program
information, please visit <http://investorforum.bio.org>. Registration is complimentary for
qualified investors and credentialed members of the media.

Advance media registration is now available at
https://www.compusystems.com/servlet/ar?evt_uid=693&site=MEDIA.

The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

Intellectual Property Council Committee Fall Conference and Meeting

October 20-22, 2008
Orlando, Fla.

BIO HR Conference 2008

October 26-28, 2008
San Diego, Calif.

BIO-LES Advanced Business Development Course

October 27-29, 2008
San Francisco, Calif.

Seventh Annual BIO Investor Forum

October 29-31, 2008
San Francisco, Calif.

Advanced Business Development Course

November 14-16, 2008
Mannheim/Heidelberg, Germany

BIO-Europe 2008

November 17-19, 2008
Mannheim/Heidelberg, Germany

2009 BIO International Convention

May 18-21, 2009
Atlanta, Ga.

###